Istradefylline (KW-6002) is a selective antagonist at the A2A receptor. It has been found to be useful in the treatment of Parkinson's disease. Istradefylline reduces dyskinesia resulting from long-term treatment with classical antiparkinson drugs such as levodopa. Istradefylline is an analog of caffeine.
仅供研究使用。 我们不向患者出售。
化学信息
| 名称 | Istradefylline |
| Iupac 化学名称 | 8-[(E)-2-(3,4-dimethoxyphenyl)vinyl]-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione |
| 同义词 | KW6002; KW 6002 |
| 英文同义词 | KW6002; KW 6002 |
| 分子式 | C20H24N4O4 |
| 分子量 | 384.43 |
| Smile | COC=1C=C(C=CC1OC)/C=C/C1=NC=2N(C(N(C(C2N1C)=O)CC)=O)CC |
| InChiKey | IQVRBWUUXZMOPW-PKNBQFBNSA-N |
| InChi | InChI=1S/C20H24N4O4/c1-6-23-18-17(19(25)24(7-2)20(23)26)22(3)16(21-18)11-9-13-8-10-14(27-4)15(12-13)28-5/h8-12H,6-7H2,1-5H3/b11-9+ |
| Cas号 | 155270-99-8 |
| 相关CAS号 | |
| 外观性状 | Solid powder |
| 纯度 | 98% by HPLC |
| 存储 | -20 ºC for 3 years |
| 可溶性 | Soluble in DMSO, not in water |
| 处理方式 | |
| 运输条件 | Shipped under ambient temperature |
| 海关编码 | |
| Targets | |
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study | |